Roger, P.-M.; Lesselingue, D.; Gérard, A.; Roghi, J.; Quint, P.; Un, S.; Chincholle, A.; Assi, A.; Bouchard, O.; Javaudin, V.; Denes, E. Antibiotic Consumption 2017–2022 in 30 Private Hospitals in France: Impact of Antimicrobial Stewardship Tools and COVID-19 Pandemic. Antibiotics2024, 13, 180.
Roger, P.-M.; Lesselingue, D.; Gérard, A.; Roghi, J.; Quint, P.; Un, S.; Chincholle, A.; Assi, A.; Bouchard, O.; Javaudin, V.; Denes, E. Antibiotic Consumption 2017–2022 in 30 Private Hospitals in France: Impact of Antimicrobial Stewardship Tools and COVID-19 Pandemic. Antibiotics 2024, 13, 180.
Roger, P.-M.; Lesselingue, D.; Gérard, A.; Roghi, J.; Quint, P.; Un, S.; Chincholle, A.; Assi, A.; Bouchard, O.; Javaudin, V.; Denes, E. Antibiotic Consumption 2017–2022 in 30 Private Hospitals in France: Impact of Antimicrobial Stewardship Tools and COVID-19 Pandemic. Antibiotics2024, 13, 180.
Roger, P.-M.; Lesselingue, D.; Gérard, A.; Roghi, J.; Quint, P.; Un, S.; Chincholle, A.; Assi, A.; Bouchard, O.; Javaudin, V.; Denes, E. Antibiotic Consumption 2017–2022 in 30 Private Hospitals in France: Impact of Antimicrobial Stewardship Tools and COVID-19 Pandemic. Antibiotics 2024, 13, 180.
Abstract
Introduction
Our aim was to determine the impact of antimicrobial stewardship tools (AST) and COVID-19 pandemic on antibiotic consumption (AC).
Methods
We used the national software Consores to determine AC in DDD / 1000 days of hospitalization from 2017 to 2022 in voluntary private hospitals in France. The AST considered were 1/ internal guidelines 2/ list of antibiotics with restricted access 3/ presence of an antibiotic referent or 4/ an ID specialist 5/ proof of annual meeting on antimicrobial resistance. Institutions with dedicated units for COVID-19 patients were specified.
Results
In 30 institutions total AC varied from (means) 390 to 405 DDD/1000 DH from 2017 to 2022. Fluoroquinolones and amoxicillin / clavulanate consumption decreased from 50 to 36 (p = 0.003) and from 112 to 77 (p = 0.025) respectively, but consumption of piperacillin / tazobactam increased from 9 to 21 (p < 0.001). Over the study period, 10 institutions with ≤ 2 AST had lower AC compared to 20 institutions with ≥ 3 AST (p < 0.01). COVID-19 units opened in 10 institutions were associated with a trend toward higher macrolide consumption from 15 to 25 from 2017 to 2020 (p = 0.065) and with an acceleration of piperacillin / tazobactam consumption from 2020 to 2022 (p ≤ 0.003).
Conclusion
Antibiotic consumption in 30 private hospitals in France was inversely related to the number of AST. The COVID-19 pandemic was associated with limited impact on AC but special attention should be paid on piperacillin / tazobactam consumption.
Keywords
antibiotic consumption; defined daily doses; antimicrobial stewardship; tools; COVID-19
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
